Ferring Pharmaceuticals announced the launch of Nocdurna (desmopressin acetate), the first and only sublingual tablet approved in the United States for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per ni
Ferring Pharmaceuticals announced the launch of Nocdurna (desmopressin acetate), the first and only sublingual tablet approved in the United States for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per ni